Skip to main content
Window of Opportunity in PsA
TMP SMX Prophylaxis in GPA
Watch: Lupus and the Patient Perspective

Dr. Kathryn Dao talks with patient advocate Amanda Greene about her patient p

Dr. John Cush RheumNow

2 years 9 months ago
Watch: Lupus and the Patient Perspective Dr. Kathryn Dao talks with patient advocate Amanda Greene about her patient poster (PP03) on "Lupus with Slime: Improve QOL and Increase ROM in SLE with Slime" at #ACR23. https://t.co/JKU3w7sz4j https://t.co/IWHLJEi0qG
C9n @RheumNow, excelente persona. Gracias!! https://t.co/pGZnMHApQH

José Navia Dongo

2 years 9 months ago
C9n @RheumNow, excelente persona. Gracias!! https://t.co/pGZnMHApQH
Crude drug retention at 1 year was 65% for JAKi, significantly lower than for other modes of action (74%) and TNFi (77%)

Dr. Antoni Chan

2 years 9 months ago
Crude drug retention at 1 year was 65% for JAKi, significantly lower than for other modes of action (74%) and TNFi (77%). These results are driven by the severity of the disease of patients on JAKi compared to other MOA. Aymon R Abst#1692 #ACR23 @RheumNow https://t.co/LPDpWdjoLg https://t.co/Ztaz94omd9
Obs study, bDMARDs & malignancy

TNFi w/lower risk than ABA/RTX/IL6i & numerically lower than JAKs

I'm a little

Mike Putman EBRheum

2 years 9 months ago
Obs study, bDMARDs & malignancy TNFi w/lower risk than ABA/RTX/IL6i & numerically lower than JAKs I'm a little skeptical... KM curves diverged w/~45 days, seems implausible? Agree w/first author, possible channeling bias @RheumNow #ACR23 Abstr 1678 https://t.co/1uL3j6kTSj
×